Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10022437 Modified RSV F proteins and methods of their use

Patent 10022437 was granted and assigned to Novavax on July, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Yingyun Wu0

Michael J. Massare0

Peter Pushko0

Ye Liu0

Bin Zhou0

Gale Smith0

Date of Patent

July 17, 2018

0

Patent Application Number

148392470

Date Filed

August 28, 2015

0

Patent Citations Received

US Patent 12083228 Methods and compositions for treating respiratory disease

0

US Patent 11541112 Coronavirus vaccine formulations

US Patent 10953089 Coronavirus vaccine formulations

0

US Patent 11052146 Modified RSV F proteins and methods of their use

US Patent 11253585 Vaccine compositions having improved stability and immunogenicity

US Patent 11253586 Coronavirus vaccine formulations

US Patent 11278612 Multivalent influenza nanoparticle vaccines

US Patent 11771755 Self-asssembling nanostructure vaccines

...

Patent Primary Examiner

Shanon A. Foley

0

Patent abstract

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10022437 Modified RSV F proteins and methods of their use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool